Eligibility criteria for HIV clinical trials and generalizability of results: The gap between published reports and study protocols

AIDS

Volumn 19, Issue 16, 2005, Pages 1885-1896

  Gandhi, Monica ^a   Ameli, Niloufar ^a   Bacchetti, Peter ^a   Sharp, Gerald B ^b   French, Audrey L ^c   Young, Mary ^d   Gange, Stephen J ^e   Anastos, Kathryn ^f   Holman, Susan ^g   Levine, Alexandra ^h   Greenblatt, Ruth M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Jr Hospital of Cook County   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^g STATE UNIVERSITY OF NEW YORK   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical trials; Eligibility criteria; Generalizability; HIV; Protocols; Publications

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMMUNITY CARE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MEDICAL PRACTICE; PRIORITY JOURNAL; UNITED STATES;

EID: 27544501319     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189866.67182.f7     Document Type: Article

References (72)

1. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003; 33:321-328.
2. Anon. Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. Lancet 1999; 353:2061-2064.
3. Deeks S, Hecht F, Swanson M, Elbeik T, Loftus R, Cohen P, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
4. Sulkowski MS. Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. Hepatology 2004; 39:906-908.
5. el-Sadr VV, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA 1992; 267:954-957.
6. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med 1997; 12:150-157.
7. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346:1373-1382.
8. Diaz T, Chu SY, Sorvillo F, Mokotoff E, Davidson AJ, Samuel MC, et al. Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:562-568.
9. Hankins C, Lapointe N, Walmsley S. Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group. CMAJ 1998; 159:1359-1365.
10. Pedone C, Lapane KL. Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Commitee's guidelines on hypertension. BMC Public Health 2003; 3:24.
11. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis 2004; 192:87-94.
12. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162:1682-1688.
13. Sweeney KG, Gray DP, Steele R, Evans P. Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. Br J Gen Pract 1995; 45:153-158.
14. Fossa SD, Skovlund E. Selection of patients may limit the generalizability of results from cancer trials. Acta Oncol 2002; 41:131-137.
15. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, Massaro J, Silbershatz H, Wilson PW. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study. Arch Intern Med 2001; 161:949-954.
16. Sharpe N. Clinical trials and the real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther 2002; 16:75-77.
17. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276:637-639.
18. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002; 287:2801-2804.
19. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002; 137:10-16.
20. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomised and non-randomised studies: a systematic review, Chapter 4 and Appendix 4. Health Technol Assess 1998; 2 (i-iv):1-124.
21. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990; 89:630-638.
22. Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995; 155:745-754.
23. Moore D, Goodall R, Ives N, Hooker N, Gazzard B, Easterbrook P. How generalizable are the results of large randomized controlled trials of antiretroviral therapy? HIV Med 2000; 1:149-154.
24. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Croup. N Engl J Med 1997; 337:15-21. [ACTG protocol 159 (1992): A randomized double blind protocol comparing amphotericin b with flucytosine to amphotericin b alone followed by a comparison of fluconazole and itracaonzole in the treatment of acute cryptococcal meningitis.]
25. Krown SE, Ei P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002; 22:295-303. [ACTG protocol 206 (1992): A randomized Phase II trial to determine the safety, tolerance and efficacy of two doses of interferon alpha combined with didanosine in patients with Kaposi's sarcoma.]
26. Benson CA, Williams PE, Currier JS, Holland F, Mahon EF, MacGregor RR, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234-1243. [ACTG protocol 223 (1994): A Phase II/III prospective, multicenter, randomized, controlled trial comparing the safety and efficacy of three clarithromycin- containing combination drug regimens for the treatment of disseminated MAC disease in persons with AIDS.]
27. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34:1243-1250. [ACTG protocol 237 (1994): A Phase II randomized open-label trial of atovaquone plus pyrimethamine and atovaquone plus sulfadiazine for the treatment of acute toxoplasmic encephalitis.]
28. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338:1345-1351. [ACTG protocol 243 (1994): A Phase II multicenter study comparing antiretroviral therapy alone to antiretroviral therapy plus cytosine arabinoside for the treatment of progressive multifocal leukoencephalopathy (PME) in human immunodeficiency virus infected subjects.]
29. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487-1493. [ACTG protocol 251 (1994): Thalidomide for treatment of oral and esophageal aphthous ulcers and HIV viremia in patients with HIV infection.]
30. Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr 1999; 21:281-292. [ACTC protocol 261 (1994): A Phase II double-blind study of delavirdine (DLV) in combination with zidovudine (ZDV) and/or didanosine (ddI) versus ZDV and ddI combination therapy.]
31. 3 CD4 cells and no previous nucleoside experience.]
32. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-79. [ACTG protocol 315 (1996): A pilot study to evaluate the immunologic consequences of highly active antiretroviral therapy (HAART) consisting of ritonavir (ABT-538), zidovudine (ZDV), and lamivudine (3TC) in moderately advanced, HIV-1 disease.]
33. 3 and ≥ 3 months of prior zidovudine.]
34. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339:1261-1268. [ACTG protocol 343 (1996): A prospective randomized double blind trial of three maintenance regimens for HIV infected patients receiving induction therapy with zidovudine, lamivudine, and indinavir.]
35. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999; 179:808-816. [ACTG protocol 347 (1997): A randomized, double-blind phase 2 study of VX-478 (amprenavir) monotherapy vs VX-478 plus ZDV plus 3TC in HIV infected individuals.]
36. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182:1375-1384. [ACTG protocol 359 (1997): Activity of the soft gelatin capsule of saquinavir (SQV) in combination with ritonavir (RTV) or nelfinavir and combinations of delavirdine (DLV), and/or adefovir dipivoxil in HIV infected subjects with prior indinavir (IDV) use and viral loads of >/= 2000 and
37. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001; 345:398-407. [ACTG protocol 364 (1997): Comparison of the virologic efficacy of nelfinavir and/or DMP-266 (efavirenz) in combination with one or two nucleoside analogs in nucleoside experienced subjects: a rollover study of ACTG 302/303.]
38. Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, et al. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. AIDS 2000; 14:1553-1561. [ACTC protocol 370 (1997): Virologic and immunologic activity of continued lamivudine (3TC) vs delavirdine (DLV) in combination with indinavir and zidovudine (ZDV) or stavudine (d4T) in 3TC-experienced patients.]
39. Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JC, et al. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis 2001; 183:715-721. [ACTG protocol 373 (1997): A Phase II study of 1) amprenavir plus 3TC plus ZDV (or d4T); 2) indinavir plus nevirapine plus 3TC plus stavudine or 3) other treatment regimens in subjects previously treated with amprenavir.]
40. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-634. [ACTG protocol 388 (1998): A Phase III randomized, controlled trial of EFV or NFV in combination with 3TC/ZDV and IDV in HIV infected subjects with CD4 ≤ 200 or vl > 80 000.]
41. Hammer S, Vaida F, Bennett K, Holohan M, Sheiner L, Eron J, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180. [ACTG protocol 398 (1998): A Phase II, randomized trial of amprenavir as part of dual protease inhibitor regimens (placebo-controlled), in combination with abacavir, efavirenz and adefovir dipivoxil in HIV-infected subjects with prior exposure to approved protease inhibitors and loss of virologic suppression as reflected by a plasma HIV-1 RNA concentration ≥ 1,000 copies/ml.]
42. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303. [ACTG protocol 384 (1998): Study of protease inhibitor and/or non-nucleoside reverse transcriptase inhibitor with dual nucleosides in initial therapy of HIV infection.]
43. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861. [ACTG protocol 5095 (2001): Phase III, randomized, double-blind comparison of three protease inhibitor-sparing regimens for the initial treatment of HIV infection.]
44. Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1994; 330:657-662. [CPCRA protocol 002 (1991): Randomized trial of ddI and ddC in HIV-infected patients who were intolerant or failed ZDV therapy.]
45. Gordin F, Chaisson RE, Matts JP, Korvick JA, Neaton JD, Crane LR, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283:1445-1450. [CPCRA protocol 004 (1994): International, multicenter randomized open-label two-arm (isoniazid versus rifampin/pyrazinamide) comparative trial.]
46. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337:315-320. [CPCRA protocol 005 (1994): Prophylaxis against tuberculosis in patients with HIV infection and anergy, but with suspected tuberculous infection.]
47. El-Sadr WM, Luskin-Hawk R, Yurik TM, Walker J, Abrams D, John SL, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999; 29:775-783. [CPCRA protocol 006 (1994): Compare the safety and efficacy of two dosage regimens (daily and thrice weekly) of trimethoprim-sulfamethoxazole (TMS) in the prevention of PCP in high-risk HIV-infected patients.].
48. 3.]
49. 3.]
50. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280:1590-1595. [CPCRA protocol 022 (1994): To evaluate the separate and combined efficacy of a standard acupuncture regimen and amitriptyline on the relief of pain due to peripheral neuropathy and on the quality of life of HIV-infected patients.]
51. Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12:269-277. [CPCRA protocol 023 (1995): To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against CMV retinal and gastrointestinal mucosal disease in HIV-infected patients in severe immunosuppression.]
52. El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085-1092. [CPCRA protocol 048 (1999): A randomized, double-blind, placebo-controlled trial of prophylaxis for disseminated Mycobacterium avium complex disease and bacterial pneumonia versus deferred prophylaxis in HIV-infected patients who experience rebound in CD4+ cell count due to active antiretroviral therapy.]
53. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846. [CPCRA protocol 064 (2000): A randomized study of a prescribed 4-month structured treatment interruption (STI) followed by initiation of a new antiretroviral regimen versus immediate initiation of a new antiretroviral regimen in HIV-infected patients with multidrug resistance (MDR) virus.]
54. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93. [CPCRA protocol 046 (1997): A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) compared with antiretroviral management without plasma GART.]
55. 3 or a lifetime nadir of < 50.]
56. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9:117-125.
57. Women's Interagency HIV Study (WIHS) website: https://state-piaps.jhsph. edu/wihs/
58. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet 1999; 353:743-746.
59. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999; 319:312-315.
60. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy 1999; 4:112-121.
61. Yusuf S, Held P, Teo KK, Toretsky ER. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med 1990; 9:73-83. discussion 83-86.
62. Chalmers TC. Ethical implications of rejecting patients for clinical trials. JAMA 1990; 263:865.
63. Weijer C. Selecting subjects for participation in clinical research: one sphere of justice. J Med Ethics 1999; 25:31-36.
64. Pardo M, Ruiz M, Gimeno A, Navarro L, Garcia A, Tarazona M, et al. Gender bias in clinical trials of AIDS drugs. XIV International AIDS Conference. Barcelona, July, 2002 [abstract We-PeB5964].
65. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol 2000; 53:973-979.
66. Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991; 151:501-505.
67. Weijer C, Freedman B, Shapiro S, Fuks A, Skrutkowska M, Sigurjonsdottir M. Assessing the interpretation of criteria for clinical trial eligibility: a survey of oncology investigators. Clin Invest Med 1998; 21:17-26.
68. Bangsberg D, Hecht F, Clague H, Charlebois E, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:435-442.
69. Bangsberg D, Hecht F, Charlebois E, Zolopa A, Holodiny M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
70. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the Millennium. JAMA 2001; 285:1186-1192.
71. Fauci AS. AIDS-challenges to basic and clinical biomedical research. Acad Med 1989; 64:115-119.
72. HIV/AIDS Surveillance Supplemental Report - Cases of HIV Infection and AIDS in the United States, by Race/Ethnicity, 1998-2002. http://www.cdc.gov/hiv/ stats/Cases_HIV -Infection_AIDS-by-Race_Ethnicity_1998-2002.pdf 2004